Results overview: Found 9 records in 0.02 seconds.
Articles, 9 records found
Articles 9 records found  
1.
19 p, 1.6 MB Strategies to design clinical studies to identify predictive biomarkers in cancer research / Perez-Gracia, Jose Luis (Clínica Universidad de Navarra) ; Sanmamed, Miguel F. (Yale University School of Medicine) ; Bosch, Ana (Lund University) ; Patiño-Garcia, Ana (Clínica Universidad de Navarra) ; Schalper, Kurt A. (Yale School of Medicine) ; Segura, Victor (Universidad de Navarra) ; Bellmunt, Joaquim (Dana-Farber Cancer Institute and Harvard Medical School) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Sweeney, Christopher J. (Dana-Farber Cancer Institute and Harvard Medical School) ; Choueiri, Toni K. (Dana-Farber Cancer Institute and Harvard Medical School) ; Martín Jiménez, Miguel (Hospital Gregorio Marañón. Instituto de Investigación Sanitaria) ; Fusco, Juan Pablo (Clínica Universidad de Navarra) ; Rodriguez-Ruiz, Maria Esperanza (Universidad de Navarra) ; Calvo, Alfonso (Universidad de Navarra) ; Prior, Celia (Universidad de Navarra) ; Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Pio, Ruben (Universidad de Navarra) ; Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia) ; Gonzalez Hernandez, Alvaro (Clínica Universidad de Navarra) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Piulats, Jose María (Institut Català d'Oncologia) ; Gurpide, Alfonso (Universidad de Navarra) ; Andueza, Mapi (Clínica Universidad de Navarra) ; de Velasco, Guillermo (Dana-Farber Cancer Institute and Harvard Medical School) ; Pazo, Roberto (Hospital Universitario Miguel Servet (Saragossa)) ; Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ; Nicolas, Pilar (Universidad del País Vasco) ; Abad-Santos, Francisco (Instituto de Investigación Sanitaria la Princesa (IP)) ; Garcia-Donas, Jesus (Centro Integral Oncológico HM Clara Campal) ; Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ; Pajares, María J. (Universidad de Navarra) ; Suárez, Cristina (Hospital Universitari Vall d'Hebron) ; Colomer, Ramon (Hospital Universitario de la Princesa (Madrid)) ; Montuenga, Luis M. (Universidad de Navarra) ; Melero, Ignacio (Universidad de Navarra) ; Universitat Autònoma de Barcelona
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. [...]
2017 - 10.1016/j.ctrv.2016.12.005
Cancer Treatment Reviews, Vol. 53 (january 2017) , p. 79-97  
2.
22 p, 1.1 MB MyD88 and TLR4 Expression in Epithelial Ovarian Cancer / Block, Matthew S. (Mayo Clinic) ; Vierkant, Robert A. (Mayo Clinic) ; Rambau, Peter F. (Catholic University of Health and Allied Sciences-Bugando) ; Winham, Stacey J. (Mayo Clinic) ; Wagner, Philipp (Tübingen University Hospital) ; Traficante, Nadia (the University of Melbourne) ; Toloczko, Aleksandra (Pomeranian Medical University) ; Tiezzi, Daniel G. (University of São Paulo) ; Taran, Florin Andrei (Tübingen University Hospital) ; Sinn, Peter (Heidelberg University Hospital (Alemanya)) ; Sieh, Weiva (Icahn School of Medicine at Mount Sinai) ; Sharma, Raghwa ; Rothstein, Joseph H. (Icahn School of Medicine at Mount Sinai) ; Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ; Paz-Ares, Luis (Hospital 12 de Octubre (Madrid)) ; Oszurek, Oleg (Pomeranian Medical University) ; Orsulic, Sandra (Cedars-Sinai Medical Center) ; Ness, Roberta B. (University of Texas School of Public Health) ; Nelson, Gregg (University of Calgary) ; Modugno, Francesmary (Magee-Womens Research Institute and University of Pittsburgh Cancer Institute) ; Menkiszak, Janusz (Pomeranian Medical University) ; McGuire, Valerie (Stanford University School of Medicine) ; McCauley, Bryan M. (Mayo Clinic) ; Mack, Marie (University of Cambridge) ; Lubinski, Jan (International Hereditary Cancer Center) ; Longacre, Teri A. (Stanford University) ; Li, Zheng (the Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital)) ; Lester, Jenny (Cedars-Sinai Medical Center) ; Kennedy, Catherine J. (Westmead Hospital) ; Kalli, Kimberly R. (Mayo Clinic) ; Jung, Audrey Y. (German Cancer Research Center (DKFZ)) ; Johnatty, Sharon E. (QIMR Berghofer Medical Research Institute (Brisbane, Austràlia)) ; Jimenez-Linan, Mercedes (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Jensen, Allan (Danish Cancer Society Research Center) ; Intermaggio, Maria P. (University of New South Wales) ; Hung, Jillian ; Herpel, Esther (University of Heidelberg) ; Hernandez, Brenda Y. (University of Hawaii) ; Hartkopf, Andreas D. (Tübingen University Hospital) ; Harnett, Paul R. ; Ghatage, Prafull (University of Calgary) ; García-Bueno, José M. (Complejo Hospitalario Universitario de Albacete) ; Gao, Bo (University of Sydney) ; Fereday, Sian ; Eilber, Ursula (German Cancer Research Center (DKFZ)) ; Edwards, Robert P. (University of Pittsburgh School of Medicine) ; de Sousa, Christiani B. (University of São Paulo) ; de Andrade, Jurandyr M. (University of São Paulo) ; Chudecka-Glaz, Anita (Pomeranian Medical University) ; Chenevix-Trench, Georgia ; Cazorla, Alicia (Hospital Universitario Fundación Jiménez Díaz) ; Brucker, Sara Y. (Tübingen University Hospital) ; Bowtell, David D. ; Green, A. ; Webb, P. ; De Fazio, Anna ; Gertig, D. ; Moore, S. ; Harrap, K. ; Sadkowsky, T. ; Pandeya, N. ; Malt, M. ; Mellon, A. ; Robertson, R. ; Vanden Bergh, T. ; Jones, M. ; Mackenzie, P. ; Maidens, J. ; Nattress, K. ; Chiew, Y.E. ; Stenlake, A. ; Sullivan, H. ; Alexander, B. ; Ashover, P. ; Brown, S. ; Corrish, T. ; Green, L. ; Jackman, L. ; Ferguson, K. ; Martin, K. ; Martyn, A. ; Ranieri, B. ; White, J. ; Jayde, V. ; Mamers, P. ; Bowes, L. ; Galletta, L. ; Giles, D. ; Hendley, J. ; Alsop, K. ; Schmidt, T. ; Shirley, H. ; Ball, C. ; Young, C. ; Viduka, S. ; Tran, H. ; Bilic, Sanela ; Glavinas, Lydia 700 1_ ; Stuart-Harris, R. ; Kirsten, F. ; Rutovitz, J. ; Clingan, P. ; Glasgow, A. ; Proietto, A. ; Braye, S. ; Otton, G. ; Shannon, J. ; Bonaventura, T. ; Stewart, J. ; Begbie, S. ; Friedlander, M. ; Bell, D. ; Baron-Hay, S. ; Ferrier, A. ; Gard, G. ; Nevell, D. ; Pavlakis, N. ; Valmadre, S. ; Young, B. ; Camaris, C. ; Crouch, R. ; Edwards, L. ; Hacker, N. ; Marsden, D. ; Robertson, G. ; Beale, P. ; Beith, J. ; Carter, J. ; Dalrymple, C. ; Houghton, R. ; Russell, P. ; Links, M. ; Grygiel, J. ; Hill, J. ; Brand, A. ; Byth, K. ; Jaworski, R. ; Wain, G. ; Ward, B. ; Papadimos, D. ; Crandon, A. ; Cummings, M. ; Horwood, K. ; Obermair, A. ; Perrin, L. ; Wyld, D. ; Nicklin, J. ; Davy, M. ; Oehler, M.K. ; Hall, C. ; Dodd, T. ; Healy, T. ; Pittman, K. ; Henderson, D. ; Miller, J. ; Pierdes, J. ; Blomfield, P. ; Challis, D. ; McIntosh, R. ; Parker, A. ; Brown, B. ; Rome, R. ; Allen, D. ; Grant, P. ; Hyde, S. ; Laurie, R. ; Robbie, M. ; Healy, D. ; Jobling, T. ; Manolitsas, T. ; McNealage, J. ; Rogers, P. ; Susil, B. ; Sumithran, E. ; Simpson, I. ; Phillips, K. ; Rischin, D. ; Fox, S. ; Johnson, D. ; Lade, S. ; Loughrey, M. ; O'Callaghan, N. ; Murray, W. ; Waring, P. ; Billson, V. ; Pyman, J. ; Neesham, D. ; Quinn, M. ; Underhill, C. ; Bell, R. ; Ng, L.F. ; Blum, R. ; Ganju, V. ; Hammond, I. ; Leung, Y. ; McCartney, A. ; Buck, M. ; Haviv, I. ; Purdie, D. ; Whiteman, D. ; Zeps, N. ; Alsop, Jennifer (University of Cambridge) ; Whittemore, Alice S. (Stanford University School of Medicine) ; Steed, Helen (Royal Alexandra Hospital) ; Staebler, Annette (Tübingen University Hospital) ; Moysich, Kirsten B. (Roswell Park Cancer Institute) ; Menon, Usha (University College London) ; Koziak, Jennifer M. (Alberta Health Services-Cancer Care) ; Kommoss, Stefan (Tübingen University Hospital) ; Kjaer, Susanne K. (University of Copenhagen) ; Kelemen, Linda E. (Medical University of South Carolina and Hollings Cancer Center) ; Karlan, Beth Y. (Cedars-Sinai Medical Center) ; Huntsman, David G. (British Columbia Cancer Agency) ; Høgdall, Estrid (University of Copenhagen) ; Gronwald, Jacek (Pomeranian Medical University) ; Goodman, Marc T. (Cedars-Sinai Medical Center) ; Gilks, Blake (Vancouver General Hospital and University of British Columbia) ; García, María José (Instituto de Salud Carlos III) ; Fasching, Peter A. (University Hospital Erlangen (Alemanya)) ; Deen, Suha (Nottingham University Hospitals NHS Trust) ; Chang-Claude, Jenny (University Medical Center Hamburg-Eppendorf) ; Candido dos Reis, Francisco J. (University of São Paulo) ; Campbell, Ian G. (University of Melbourne) ; Brenton, James D. (Cambridge Experimental Cancer Medicine Centre) ; Benitez, Javier (Instituto de Salud Carlos III) ; Pharoah, Paul D.P. (University of Cambridge) ; Köbel, Martin (University of Calgary) ; Ramus, Susan J. (Garvan Institute) ; Goode, Ellen L. (Mayo Clinic) ; Universitat Autònoma de Barcelona
To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival. [...]
2018 - 10.1016/j.mayocp.2017.10.023
Mayo Clinic Proceedings, Vol. 93 Núm. 3 (january 2018) , p. 307-320  
3.
7 p, 485.5 KB Impact of the COVID-19 pandemic on the care of cancer patients in Spain / Amador, Mariluz (Asociación Española Contra el Cancer) ; Matias-Guiu, X. (Hospital Universitari de Bellvitge) ; Sancho-Pardo, Gemma (Institut d'Investigació Biomèdica Sant Pau) ; Contreras Martinez, J. (Hospital Regional Universitario de Málaga) ; de la Torre-Montero, J.C. (Universidad Pontificia Comillas) ; Peñuelas Saiz, A. (Hospital Universitari Vall d'Hebron) ; Garrido, P. (Hospital Universitario Ramón y Cajal (Madrid)) ; García-Sanz, Ramón (Instituto de Investigación Biomédica de Salamanca) ; Rodríguez-Lescure, None (Hospital Universitario de Elche) ; Paz-Ares, L. (Hospital Universitario 12 de Octubre (Madrid))
Background: Studies evaluating the effects of the COVID-19 pandemic on public healthcare systems are limited, particularly in cancer management. As no such studies have been carried out in Spain, our objective is to describe and quantify the impact of the COVID-19 pandemic on cancer patients in Spanish hospitals during the first wave of the pandemic. [...]
2021 - 10.1016/j.esmoop.2021.100157
ESMO open, Vol. 6 Núm. 3 (june 2021) , p. 100157  
4.
11 p, 555.4 KB LungBEAM : A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology / Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ; Paz-Ares, Luis (Universidad Complutense de Madrid) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Trigo, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ; Garcίa-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; González-Larriba, José Luis (Hospital Universitario Clínico San Carlos (Madrid)) ; Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Viñolas, Núria (Hospital Clínic i Provincial de Barcelona) ; Camps, Carlos (Hospital General Universitario de Valencia) ; Insa, Amelia (Hospital Clínico Universitario) ; Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ; Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ; Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; López-Brea, Marta (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Palacios, José (Hospital Universitario Ramón y Cajal (Madrid)) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron)
Objectives: The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). [...]
2021 - 10.1002/cam4.4135
Cancer Medicine, Vol. 10 Núm. 17 (september 2021) , p. 5878-5888  
5.
16 p, 758.5 KB Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression : A network meta-analysis / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Cobo, Manuel (Hospital Regional Universitario de Málaga) ; Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Marquez-Medina, Diego (Hospital Universitario Miguel Servet (Saragossa)) ; Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ; Casal-Rubio, Joaquín (Hospital Álvaro Cunqueiro (Vigo)) ; Moran-Bueno, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Pérez-Parente, Diego (Medical Affairs Department. Roche Farma S.A) ; Ruiz-Gracia, Pedro (Medical Affairs Department. Roche Farma S.A) ; Arroyo, Marta Marina (Medical Affairs Department. Roche Farma S.A) ; Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid))
Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selec-tion of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). [...]
2021 - 10.3390/jcm10071365
Journal of clinical medicine, Vol. 10 Núm. 7 (april 2021) , p. 1365  
6.
13 p, 2.1 MB Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma : the ROSING Study / Conde, Esther (Hospital Universitario HM Sanchinarro (Madrid)) ; Hernández, Susana (Hospital Universitario HM Sanchinarro (Madrid)) ; Martinez, Rebeca (Hospital Universitario HM Sanchinarro (Madrid)) ; Angulo, Bárbara (Hospital Universitario HM Sanchinarro (Madrid)) ; de Castro, Javier (Hospital Universitario La Paz (Madrid)) ; Collazo-Lorduy, Ana (Hospital Universitario HM Sanchinarro (Madrid)) ; Jimenez, Beatriz (Hospital Universitario HM Sanchinarro (Madrid)) ; Muriel, Alfonso (Hospital Universitario Ramón y Cajal (Madrid)) ; Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Aranda, Ignacio (Instituto de Investigación Sanitaria y Biomédica de Alicante) ; Massuti, Bartomeu (Instituto de Investigación Sanitaria y Biomédica de Alicante) ; Rojo, Federico (Centro de Investigación Biomédica en Red de Cáncer) ; Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Sansano, Irene (Hospital Universitari Vall d'Hebron) ; Garcia, Felip (Quironsalud Hospital) ; Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ; Mancheño, Nuria (Hospital Universitari i Politècnic La Fe (València)) ; Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ; Sanz, Julián (Hospital Clínico San Carlos (Madrid)) ; Gonzalez-Larriba, José Luis (Hospital Clínico San Carlos (Madrid)) ; Atienza-Cuevas, Lidia (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ; Arriola-Arellano, Esperanza (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ; Abdulkader, Ihab (Complejo Hospitalario Universitario de Santiago de Compostela) ; Garcia-Gonzalez, Jorge (Complejo Hospitalario Universitario de Santiago de Compostela) ; Camacho, Carmen (Insular Materno-Infantil University Hospital Complex) ; Rodríguez-Abreu, Delvys (Insular Materno-Infantil University Hospital Complex) ; Teixidó, Cristina (Hospital Clínic i Provincial de Barcelona) ; Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ; Gonzalez-Piñeiro, Ana (Hospital Álvaro Cunqueiro (Vigo)) ; Lázaro, Martín (Hospital Álvaro Cunqueiro (Vigo)) ; Lozano, María Dolores (Clínica Universidad de Navarra) ; Gurpide, Alfonso (Clínica Universidad de Navarra) ; Gómez-Román, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Lopez-Brea, M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ; Salido, Marta (Hospital del Mar (Barcelona, Catalunya)) ; Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ; Company, Amparo (Hospital Clínic Universitari (València)) ; Insa, Amelia (Hospital Clínic Universitari (València)) ; Esteban-Rodriguez, Isabel (Hospital Universitario La Paz (Madrid)) ; Saiz, Mónica (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Azkona, Eider (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Álvarez, Ramiro (Hospital Universitario Miguel Servet (Saragossa)) ; Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ; Plaza, María Luz (Hospital Universitario de Gran Canaria Dr. Negrín) ; Aguiar de Sousa, Diana (Hospital Universitario de Gran Canaria Dr. Negrín) ; Enguita, Ana Belén (Hospital Universitario 12 de Octubre (Madrid)) ; Benito, Amparo (Hospital Universitario Ramón y Cajal (Madrid)) ; Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ; Lopez-Rios, Fernando (Hospital Universitario HM Sanchinarro (Madrid)) ; Universitat Autònoma de Barcelona
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. [...]
2019 - 10.1016/j.jtho.2019.07.005
Journal of Thoracic Oncology, Vol. 14 Núm. 12 (december 2019) , p. 2120-2132  
7.
11 p, 388.8 KB Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab / Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa) ; Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Zhu, A. X (Massachusetts General Hospital (Boston)) ; Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ; Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ; Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ; Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ; Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ; Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ; Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942  
8.
13 p, 2.3 MB The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients / Gayarre, Javier (Centro Nacional de Investigaciones Oncológicas) ; Kamieniak, Marta M. (Centro Nacional de Investigaciones Oncológicas) ; Cazorla-Jiménez, Alicia (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Muñoz-Repeto, Ivan (Centro Nacional de Investigaciones Oncológicas) ; Borrego, Salud (Centro de Investigación Biomédica en Red de Enfermedades Raras) ; García Donas, J (Centro Integral Oncológico Clara Campal-HM CIOCC (Madrid, Espanya)) ; Hernando, Susana (Hospital Universitario Fundación Alcorcón) ; Robles-Díaz, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; García-Bueno, José María (Complejo Hospitalario Universitario de Albacete) ; Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ; Hernández-Agudo, Elena (Centro Nacional de Investigaciones Oncológicas) ; Heredia Soto, Victoria (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Márquez-Rodas, Ivan (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ; Echarri, María José (Hospital Universitario Severo Ochoa) ; Lacambra-Calvet, Carmen (Hospital Universitario Severo Ochoa) ; Sáez, Raquel (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ; Cusidó, Maite (Hospital Universitario Quirón-Dexeus) ; Redondo, Andrés (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Hardisson, David (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Mendiola, Marta (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Palacios, José (Hospital Universitario Ramón y Cajal (Madrid)) ; Benitez, Javier (Centro de Investigación Biomédica en Red de Enfermedades Raras) ; Garcia, Maria José (Centro de Investigación Biomédica en Red de Enfermedades Raras) ; Universitat Autònoma de Barcelona. Departament de Medicina
We aimed to evaluate the prognostic and predictive value of the nucleotide excision repair-related gene GTF2H5, which is localized at the 6q24. 2-26 deletion previously reported by our group to predict longer survival of high-grade serous ovarian cancer patients. [...]
2015 - 10.3802/jgo.2016.27.e7
Journal of Gynecologic Oncology, Vol. 27 (november 2015)  
9.
14 p, 1.9 MB Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer / Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ; Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Calvo, Emiliano (Centro Integral Oncológico Clara Campal-HM CIOCC (Madrid, Espanya)) ; Seoane Suárez, Joan (Hospital Universitari Vall d'Hebron) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Cleverly, Ann (Eli Lilly and Company) ; Pillay, N. Sokalingum (Eli Lilly and Company) ; Desaiah, Durisala (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Paz-Ares, Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ; Blakeley, Jaishri (Johns Hopkins University) ; Lahn, Michael M.. (Eli Lilly and Company) ; Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.